Welcome to our dedicated page for EPZM news (Ticker: EPZM), a resource for investors and traders seeking the latest updates and insights on EPZM stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EPZM's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EPZM's position in the market.
Epizyme (NASDAQ: EPZM), a biopharmaceutical company, announced participation in two investor conferences in March. Shefali Agarwal, Chief Medical Officer, will join the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 9:10 am EST for a panel discussion. Grant Bogle, CEO, will host a fireside chat at the Barclays Global Healthcare Conference on March 15, 2022, at 2:05 pm EST. Live webcasts will be available on the company's website and archived for 60 days.
Epizyme reported 4Q 2021 net product revenue of $11.6 million and $30.9 million for FY 2021, including sales for clinical trials.
In January 2022, the company raised $85 million in a public offering, extending its cash runway into 3Q 2023.
Operational changes, including workforce reductions, aim to optimize expenses, projecting total non-GAAP adjusted operating expenses between $160-180 million for 2022.
Despite a net loss of $50.7 million for 4Q 2021, management remains optimistic about the commercialization and development of TAZVERIK.
Epizyme, a biopharmaceutical company, announced a conference call scheduled for March 1, 2022, at 8:30 a.m. ET to discuss its Q4 and full year 2021 financial results. The call will provide investors with a business update and can be accessed via phone or a live webcast. Epizyme focuses on developing novel epigenetic therapies aimed at revolutionizing cancer treatment. The company aims to deliver effective, patient-specific oral medicines that change standard-of-care.
Epizyme, Inc. (Nasdaq: EPZM) announced an underwritten public offering of 56,666,667 shares at $1.50 each, aiming for gross proceeds of approximately $85 million. The offering's net proceeds will support global development and commercialization of tazemetostat, including ongoing clinical trials in various cancers, and fund other corporate purposes. The offering is set to close on January 31, 2022, subject to customary conditions. A 30-day option for underwriters to purchase an additional 8,500,000 shares is also included.
Epizyme, Inc. (Nasdaq: EPZM) announced its intention to conduct an underwritten public offering of common stock, with an option for underwriters to purchase an additional 15%. The proceeds will fund global development and commercialization of tazemetostat and its ongoing clinical trials for various cancers. The offering is subject to market conditions, and Jefferies is leading the offering process. The shares will be sold under a previously filed shelf registration statement with the SEC. This offering or its completion is uncertain, depending on market conditions.
Epizyme has released its preliminary revenue expectations for TAZVERIK, forecasting net product revenue between
Epizyme, Inc. (NASDAQ: EPZM) presented updated safety and activity data from the Phase 1b trial of TAZVERIK® (tazemetostat), in combination with rituximab and lenalidomide, for patients with relapsed/refractory follicular lymphoma at the 2021 ASH Annual Meeting. The trial included 40 patients, showing an impressive objective response rate of 91.4%, with a complete response rate of 37.1%. No new safety concerns were identified. The study is set to move to a randomized Phase 3 component to evaluate the efficacy further.
Epizyme, Inc. (NASDAQ: EPZM) announced preclinical data and the Phase 1/1b trial design for its first-in-class oral SETD2 inhibitor, EZM0414, targeting adult patients with relapsed or refractory multiple myeloma (MM) or diffuse large B-cell lymphoma (DLBCL). Presented at the ASH Annual Meeting, results showed EZM0414 significantly reduced growth in various MM cell lines and demonstrated potential synergy with standard therapies. The Phase 1 trial will assess safety and optimal dosing, enrolling up to 36 patients. This initiative aims to address the unmet needs in treating aggressive B-cell malignancies.
Epizyme, Inc. (Nasdaq: EPZM) announced new data from its oncology portfolio will be presented at the 63rd American Society of Hematology Annual Meeting in Atlanta, Georgia, from December 11 to 14, 2021. Highlights include trial designs and combination studies on tazemetostat for follicular lymphoma and preclinical data on EZM0414, a novel SETD2 inhibitor targeting multiple myeloma and DLBCL. Key presentations include interim results from the SYMPHONY-1 study and the trial design for SET-101, showcasing the role of epigenetics in cancer treatment.
Epizyme, Inc. has announced the appointment of two new members to its Board of Directors: Roy A. Beveridge, M.D., a clinical oncology executive, and Carol Stuckley, M.B.A., a seasoned pharmaceutical and financial leader. Beveridge brings over 30 years of experience in oncology and healthcare policy, while Stuckley offers 25 years of financial expertise from Pfizer. The company also announced the resignation of Andrew R. Allen, M.D., Ph.D., effective November 16, 2021. The leadership changes aim to enhance Epizyme's focus on epigenetic therapies and support its growth trajectory.
FAQ
What is the market cap of EPZM (EPZM)?
